NCT01506661View on ClinicalTrials.gov

Safety of Zostavax Vaccination in Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

October 31, 2018

Conditions
Rheumatoid ArthritisVaricella Zoster
Interventions
DRUG

Zostavax (varicella zoster virus) vaccine

Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit

Trial Locations (1)

73104

Oklahoma Medical Research Foundation, Oklahoma City

All Listed Sponsors
lead

Oklahoma Medical Research Foundation

OTHER

NCT01506661 - Safety of Zostavax Vaccination in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter